HARVARD BIOSCIENCE, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
HARVARD BIOSCIENCE, INC. (HBIO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.00 per share for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2023-11-07
- HARVARD BIOSCIENCE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00.
- HARVARD BIOSCIENCE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $0.00.
- HARVARD BIOSCIENCE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- HARVARD BIOSCIENCE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $2.58, a 32.11% decline year-over-year.
- HARVARD BIOSCIENCE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $0.00.
- HARVARD BIOSCIENCE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- HARVARD BIOSCIENCE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $2.61, a 20.43% decline from fiscal 2019.
- HARVARD BIOSCIENCE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $3.28, a 0.00% change from fiscal 2018.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2023-04-26 | ||||
| 2022-12-31 | $0.00 10-K · filed 2023-03-09 | ||||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | ||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | ||||
| 2020-12-31 | $2.61 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | $2.61 10-Q · filed 2020-11-06 | ||||
| 2020-06-30 | $2.61 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | $2.58 10-Q · filed 2020-05-08 | ||||
| 2019-12-31 | $3.28 10-K/A · filed 2021-03-17 | ||||
| 2019-09-30 | $3.35 10-Q · filed 2019-11-08 | ||||
| 2019-06-30 | $3.73 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | $3.80 10-Q · filed 2019-05-08 | ||||
| 2018-12-31 | $3.28 10-K · filed 2020-03-16 | $4.48 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $4.84 10-Q · filed 2018-11-01 | ||||
| 2018-06-30 | $4.45 10-Q · filed 2018-08-02 | ||||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $4.48 10-K · filed 2020-03-16 | $3.24 10-K · filed 2019-03-18 | |||
| 2017-09-30 | $2.99 10-Q · filed 2017-11-02 | ||||
| 2017-06-30 | $2.96 10-Q · filed 2017-08-03 | ||||
| 2017-03-31 | $3.25 10-Q · filed 2017-05-08 | ||||
| 2016-09-30 | $3.10 10-Q · filed 2016-11-03 | ||||
| 2013-09-30 | $5.08 10-Q · filed 2013-11-08 | ||||
| 2013-06-30 | $5.08 10-Q · filed 2013-08-09 | ||||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |